🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,425 results for “Elan” Clear

  1. 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  2. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen Technology (Ireland) UC

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  3. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen Technology (Ireland) UC

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Cancer Prevention Pharma (Ireland) Limited

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  5. AC-203, Vehicle ointment (Placebo of AC-203 Diacerein 1% Ointment, EU)

    Ology Bioservices Ireland LTD

    Generalized Epidermolysis Bullosa Simplex (EBS)

    phase 3 small molecule active

    1 trial

  6. ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  7. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  8. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen Technology (Ireland) UC

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  9. AMG 133, Placebo for AMG 133 (maridebart cafraglutide)

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  10. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen Technology (Ireland) UC

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  11. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  12. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  13. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  14. ARO-APOC3 PFS, ARO-APOC3, 0.9% Normal Saline for injection

    Arrowhead Pharmaceuticals Ireland Limited

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  15. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  16. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  17. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  18. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  19. Abrocitinib

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-Severe Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  20. Abrocitinib Placebo, Abrocitinib

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-Severe Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  21. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  22. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  23. Afinitor 5 mg tablets, PLACEBO

    Cancer Prevention Pharma (Ireland) Limited

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  24. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources